Immediate bisphosphonate use with endocrine therapy increased survival in postmenopausal early breast cancer

The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced the risk for disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer, according to new data from the ZO-FAST trial.

Read the whole article on Physorg

More from Physorg